结直肠癌筛查项目中粪便免疫化学检测阳性者口腔癌与上消化道癌的发病风险
该研究基于荷兰西部两个地区2006年至2012年10月共3轮每两年一次粪便免疫化学检测(FIT)筛查的试点数据,回顾性分析16165名筛查参与者,通过链接国家癌症登记处识别FIT后3年内发生的口腔或上消化道癌。FIT阳性者与阴性者的口腔或上消化道癌发生率无显著差异(0.37% vs 0.31%,P=0.65)。作者认为,对FIT阳性且结肠镜检查阴性者不推荐常规进行食管胃十二指肠镜检查。
要点
- FIT阳性者3年内口腔或上消化道癌发生率为0.37%(95%CI 0.19-0.76),FIT阴性者为0.31%(95%CI 0.23-0.42),两组间无显著差异(P=0.65)。
- FIT阳性且结肠镜检查阴性者中,仅0.14%在3年内被诊断为胃癌或食管癌。
- 作者不推荐对FIT阳性且结肠镜检查阴性者常规进行食管胃十二指肠镜检查。
核心结论
- 在荷兰FIT结直肠癌筛查人群中,FIT阳性者3年内被诊断上消化道癌的比例低于1%,FIT阳性与阴性者口腔或上消化道癌发生率无显著差异(P=0.65)。
- 作者据此不推荐对FIT阳性且结肠镜检查阴性者常规进行食管胃十二指肠镜检查。
研究设计与样本
- 回顾性分析荷兰西部两个地区2006年至2012年10月共3轮每两年一次FIT结直肠癌筛查试点研究的数据。
- 共纳入16165名筛查参与者,通过链接国家癌症登记处识别FIT后3年内发生口腔或上消化道癌者,并按FIT结果与结肠镜检查结果分组比较发生率。
主要发现
- 16165名筛查参与者中,链接识别出52人在FIT后3年内发生口腔或上消化道癌。
- FIT阳性者中发生8例口腔或上消化道癌(0.37%;95%CI 0.19-0.76),FIT阴性者中发生44例(0.31%;95%CI 0.23-0.42),两组发生率无显著差异(P=0.65)。
- FIT阳性且发生口腔或上消化道癌的8人中,6例在结肠镜检查阴性后诊断,2例在结肠镜检查阳性后诊断。
- 全部FIT阳性者中仅0.14%在3年内被诊断为胃癌或食管癌。
临床怎么用
- 作者不推荐对FIT阳性且结肠镜检查阴性者常规进行食管胃十二指肠镜检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: European guidelines recommend screening for colorectal cancer (CRC) using the fecal immunochemical test (FIT), with follow-up colonoscopies for individuals with positive test results. However, more than half of participants with positive results from the FIT are not found to have advanced neoplasia in the colonoscopy examination. Fecal occult blood might also come from the upper gastrointestinal (GI) tract, so perhaps we should consider esophagogastroduodenoscopy (EGD), to detect upper GI cancers. We aimed to determine how many individuals are found to have oral or upper GI cancers (oral cavity, throat, esophageal, gastric, or small bowel cancer) within 3 years after a positive or negative result from a FIT in a CRC screening program. METHODS: We performed a retrospective analysis of data from a pilot study of 3 rounds of biennial FIT-based screening for CRC in 2 regions in the west of the Netherlands, from 2006 through October 2012. Participants who developed oral or upper GI cancers were identified through linkage with the National Cancer Registry. We classified these cancers into 3 groups: those that developed in individuals with a positive result from a FIT but negative findings from colonoscopy (no advanced neoplasia), those that developed in individuals with a positive result from a FIT and a positive finding from colonoscopy (advanced neoplasia), and those that developed in individuals with negative results from a FIT. We compared oral and upper GI cancer incidence among groups. RESULTS: Among 16,165 screening participants, linkage identified 52 persons who developed an oral or upper GI cancer within 3 years after a FIT. We found no significant difference in incidence values between individuals with a positive vs a negative FIT result: 8 cancers developed in individuals with a positive result from a FIT (0.37%; 95% CI, 0.19-0.76) and 44 developed in individuals with a negative result from a FIT (0.31%; 95% CI, 0.23-0.42) (P = .65). Of the 8 individuals with a positive result from a FIT and an oral or upper GI cancer, 6 were diagnosed after negative findings from colonoscopy and 2 after positive findings from colonoscopy. We found that only 0.14% of all persons with a positive result from a FIT were diagnosed with a gastric or esophageal cancer within 3 years. CONCLUSION: In a study of individuals in the Netherlands undergoing screening for CRC by FIT, we found fewer than 1% of patients with a positive result from the FIT to receive a diagnosis of upper GI cancers within 3 years. Routine EGD investigation of individuals with positive results from a FIT and negative findings from colonoscopy is therefore not recommended. TrialRegister.nl, Number: NTR5385.
引用
- van der Vlugt M, Grobbee EJ, Bossuyt PM, et al. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program. Clin Gastroenterol Hepatol. 2018. PMID: 29427732. doi:10.1016/j.cgh.2018.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。